All In Biotech

Drug Trial Radar · NCT04091126

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

118

Actual

Start

Dec 18, 2019

Primary completion

Jun 2, 2025

Study completion Mar 10, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per dosing schedule. Participants will receive belantamab mafodotin on a schedule that is dependent on the cohort to which they are assigned. Belantamab mafodotin will be administered in combination with VRd every 3 weeks (Q3W), every 6 weeks (Q6W), or every 9 weeks (Q9W) to Cycle 8, and then in combination with Rd every 4 weeks (Q4W), every 8 weeks (Q8W), or every 12 weeks (Q12W) thereafter. Participants will complete an End of Treatment (EOT) visit at the point of study treatment discontinuation, followed by a Safety Follow-up visit 70 days after EOT.

Conditions

  • Multiple Myeloma

Interventions

  • Belantamab mafodotinDrug

    Selected doses of belantamab mafodotin will be administered as intravenous infusion.

  • BortezomibDrug

    Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.

  • LenalidomideDrug

    Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.

  • DexamethasoneDrug

    Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting Toxicities (DLTs) of Belantamab MafodotinTime frame: Up to 63 days
  2. Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 284 weeks

Locations

30 sites in 10 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Westwood, Kansas

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Madison, Wisconsin

  • GSK Investigational Site

    Newcastle, New South Wales, Australia

  • GSK Investigational Site

    Clayton, Victoria, Australia

  • GSK Investigational Site

    Fitzroy, Victoria, Australia

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    London, Ontario, Canada

  • GSK Investigational Site

    Poitiers, France

  • GSK Investigational Site

    Dresden, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Schwerin, Germany

  • GSK Investigational Site

    Tübingen, Germany

  • GSK Investigational Site

    Bologna, Italy

  • GSK Investigational Site

    Meldola FC, Italy

  • GSK Investigational Site

    Lublin, Poland

  • GSK Investigational Site

    Poznan, Poland

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Málaga, Spain

  • GSK Investigational Site

    PamplonaNavarra, Spain

  • GSK Investigational Site

    Pozuelo de AlarcOn Madr, Spain

  • GSK Investigational Site

    Santander, Spain

  • GSK Investigational Site

    Badalona, Barcelona, Spain

  • GSK Investigational Site

    Leicester, United Kingdom

  • GSK Investigational Site

    Oxford, United Kingdom

  • GSK Investigational Site

    Southampton, Hampshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.